logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Rivoceranib for locally advanced or metastatic gastric or gastro-oesophageal junction cancer – after two or more therapies

< Back

Rivoceranib for locally advanced or metastatic gastric or gastro-oesophageal junction cancer – after two or more therapies

Drugs

Cancer and Palliative Care

April 2020


Rivoceranib is in clinical development for locally advanced, unresectable or metastatic gastric or gastro-oesophageal junction cancer that has progressed since last treatment with at least two prior lines of therapies. Gastric cancer is cancer that starts anywhere in the stomach. Cancer that starts between the oesophagus (food pipe) and the stomach is gastro-oesophageal junction cancer. Locally advanced cancer means that the cancer has spread into the tissues around the stomach. Advanced or metastatic means where the cancer has spread to another part of the body such as the liver or lungs. Advanced cancers have a poor prognosis and often have no cure, but treatment may control the cancer, relieve symptoms and give the patient a good quality of life.

Rivoceranib is an oral medicine with potential anti-tumour activities. It works by binding to a receptor responsible for preventing cell movement and multiplication and decrease the tumour mass. If licensed, rivoceranib will provide an additional treatment option for patients with locally advanced, unresectable or metastatic gastric or gastrooesophageal junction cancer that has progressed since last treatment with at least two prior lines of therapies.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article



 

Connect to the Innovation Observatory

Twitter

Load More Related Posts

Get Alerts